La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Camurus Gestione

Gestione criteri di controllo 4/4

Camurus' Il CEO è Fredrik Tiberg, nominato in Jan2003, ha un mandato di 21.58 anni. possiede direttamente 2.73% delle azioni della società, per un valore di SEK 1.13B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.9 anni e 4.3 anni.

Informazioni chiave

Fredrik Tiberg

Amministratore delegato

SEK 12.1m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	21.6yrs
Proprietà del CEO	2.7%
Durata media del management	6.9yrs
Durata media del Consiglio di amministrazione	4.3yrs

Aggiornamenti recenti sulla gestione

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Recent updates

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Aug 09

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Apr 30

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Dec 09

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Fredrik Tiberg rispetto agli utili di Camurus?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	SEK 223m
Mar 31 2024	n/a	n/a	SEK 450m
Dec 31 2023	SEK 12m	n/a	SEK 431m
Sep 30 2023	n/a	n/a	SEK 460m
Jun 30 2023	n/a	n/a	SEK 408m
Mar 31 2023	n/a	n/a	SEK 115m
Dec 31 2022	SEK 10m	SEK 6m	SEK 56m
Sep 30 2022	n/a	n/a	SEK 28m
Jun 30 2022	n/a	n/a	-SEK 13m
Mar 31 2022	n/a	n/a	-SEK 69m
Dec 31 2021	SEK 10m	SEK 6m	-SEK 90m
Sep 30 2021	n/a	n/a	-SEK 142m
Jun 30 2021	n/a	n/a	-SEK 156m
Mar 31 2021	n/a	n/a	-SEK 128m
Dec 31 2020	SEK 10m	SEK 5m	-SEK 167m
Sep 30 2020	n/a	n/a	-SEK 174m
Jun 30 2020	n/a	n/a	-SEK 216m
Mar 31 2020	n/a	n/a	-SEK 284m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 290m
Sep 30 2019	n/a	n/a	-SEK 305m
Jun 30 2019	n/a	n/a	-SEK 286m
Mar 31 2019	n/a	n/a	-SEK 266m
Dec 31 2018	SEK 8m	SEK 5m	-SEK 235m
Sep 30 2018	n/a	n/a	-SEK 200m
Jun 30 2018	n/a	n/a	-SEK 208m
Mar 31 2018	n/a	n/a	-SEK 187m
Dec 31 2017	SEK 6m	SEK 4m	-SEK 191m

Compensazione vs Mercato: La retribuzione totale di Fredrik ($USD 1.17M ) è circa la media per le aziende di dimensioni simili nel mercato Swedish ($USD 1.03M ).

Compensazione vs guadagni: La retribuzione di Fredrik è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Fredrik Tiberg (61 yo)

21.6yrs

Mandato

SEK 12,056,000

Compensazione

Mr. Fredrik Tiberg has been Independent Director of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. Mr. Tiberg serves as Chief Executi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Fredrik Tiberg	President	21.6yrs	SEK 12.06m	2.73% SEK 1.1b
Jon U. Alonso	Chief Financial Officer	2.5yrs	Nessun dato	0.0025% SEK 1.0m
Torsten Malmstrom	Chief Technology Officer	11.6yrs	Nessun dato	0.060% SEK 24.6m
Rein Piir	Vice President of Investor Relations	9.6yrs	Nessun dato	Nessun dato
Maria Lundqvist	Global Head of Human Resources	3.3yrs	Nessun dato	Nessun dato
Markus Johnsson	Senior Vice President of R&D	no data	Nessun dato	0.036% SEK 14.6m
Fredrik Joabsson	Chief Business Development Officer	5.6yrs	Nessun dato	0.068% SEK 27.9m
Richard Jameson	Chief Commercial Officer	8.2yrs	Nessun dato	0.050% SEK 20.3m
Alberto Pedroncelli	Chief Medical Officer	1.2yrs	Nessun dato	Nessun dato

6.9yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di CAMX è esperto e expertise (durata media dell'incarico 6.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Fredrik Tiberg	President	22.6yrs	SEK 12.06m	2.73% SEK 1.1b
Jakob Lindberg	Independent Director	3.3yrs	SEK 350.00k	Nessun dato
Per-Olof Wallstrom	Independent Chairman of the Board	14.6yrs	SEK 750.00k	0.17% SEK 71.1m
Behshad Sheldon	Independent Director	6.3yrs	SEK 350.00k	0.0017% SEK 697.9k
Hege Hellstrom	Independent Director	4.3yrs	SEK 375.00k	0.0055% SEK 2.3m
Stefan Persson	Director	2.3yrs	SEK 375.00k	0.0053% SEK 2.2m
Erika Johnsson	Director	1.3yrs	SEK 450.00k	0.0010% SEK 424.4k

4.3yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CAMX sono considerati esperti (durata media dell'incarico 4.3 anni).

Camurus Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Technology Officer recently sold kr6.8m worth of stock

Chief Technology Officer recently sold kr845k worth of stock

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Camurus AB (Publ) Announces Board Resignations

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

President exercised options to buy kr86m worth of stock.

Recent updates

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

New minor risk - Insider selling

Chief Technology Officer recently sold kr6.8m worth of stock

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS misses analyst expectations

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Price target increased to kr283

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Vice President exercised options and sold kr178k worth of stock